Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024703
Filing Date
2020-05-12
Accepted
2020-05-12 16:45:37
Documents
55
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q stsa-10q_20200331.htm 10-Q 1964384
2 EX-31.1 stsa-ex311_8.htm EX-31.1 18842
3 EX-31.2 stsa-ex312_9.htm EX-31.2 18696
4 EX-32.1 stsa-ex321_6.htm EX-32.1 9903
5 EX-32.2 stsa-ex322_7.htm EX-32.2 9827
  Complete submission text file 0001564590-20-024703.txt   5830892

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT stsa-20200331.xml EX-101.INS 1170919
7 XBRL TAXONOMY EXTENSION SCHEMA stsa-20200331.xsd EX-101.SCH 38847
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE stsa-20200331_cal.xml EX-101.CAL 39248
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stsa-20200331_def.xml EX-101.DEF 119031
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20200331_lab.xml EX-101.LAB 317250
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20200331_pre.xml EX-101.PRE 231979
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

EIN.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39041 | Film No.: 20869706
SIC: 2834 Pharmaceutical Preparations